FDA Authorizes Gohibic Vilobelimab Injection for Hospitalized COVID-19 Adults on Mechanical Ventilation

Sterile injectable manufacturers and QA teams supporting complement-pathway biologics now have a new EUA benchmark: FDA's authorization of Gohibic (vilobelimab) on 4 April 2023 establishes specific labeling, dosing, and post-authorization safety monitoring expectations for IV-administered immunomodulators in the critical-care setting.

The authorization covers hospitalized adults when treatment is initiated within 48 hours of invasive mechanical ventilation or extracorporeal membrane oxygenation. That narrow initiation window carries direct implications for hospital pharmacy operations and cold-chain integrity at the point of care, where timing of preparation and administration must be tightly controlled against the authorized Fact Sheet for Health Care Providers.

The recommended regimen is 800 mg administered by intravenous infusion after dilution, given up to six times over the treatment course. For sterile manufacturing and fill-finish teams, the dilution requirement signals that compounding compatibility, container-closure integrity, and hold-time validation will be scrutinized under any future inspection of sites supporting this product. The clinical trial supporting the EUA demonstrated reduced mortality risk at both day 28 and day 60 versus placebo, providing the efficacy signal FDA required under 21 CFR Part 312 EUA criteria.

The adverse reaction profile is broad and clinically complex, encompassing serious bacterial, fungal, and viral infections alongside thromboembolic events, hepatic enzyme elevations, and respiratory complications. For pharmacovigilance and regulatory affairs leads, this profile defines the scope of post-authorization safety reporting obligations; any deviation from the authorized Fact Sheet in real-world administration will require documentation consistent with FDA's EUA safety monitoring framework.

CDER Center Director Patrizia Cavazzoni, M.D. confirmed COVID-19 treatments remain a stated priority for the center, a signal that regulatory review timelines for similar complement-inhibitor biologics are unlikely to slow in the near term. Manufacturers of comparable IV biologics should read the Gohibic authorization as an active reference point for FDA's current expectations on labeling specificity and risk communication under emergency authorization conditions.

The authorized Fact Sheet for Health Care Providers, the EUA Letter of Authorization, and patient-facing materials are available on FDA's Emergency Use Authorization webpage, and will serve as the primary compliance reference for any site involved in Gohibic's supply chain until a full BLA or NDA pathway is pursued.